Demographic and clinical characteristics of 2-year survivors of allogeneic HCT
| Variables . | Entire cohort, n = 1479 . | Primary diagnosis . | |||||
|---|---|---|---|---|---|---|---|
| AML, n = 429 . | CML, n = 452 . | ALL, n = 287 . | NHL, n = 53 . | SAA, n = 175 . | IEM, n = 83 . | ||
| Median age at HCT, y (range) | 25.9 (0.2-71.5) | 26.2 (0.9-61.0) | 34.3 (1.1-71.5) | 17.8 (0.5-51.9) | 37.3 (5.7-53.3) | 16.9 (1.7-46.7) | 2.6 (0.2-32.9) |
| Age at transplantation, y (%) | |||||||
| Younger than 18 | 505 (34.1) | 142 (33.1) | 35 (7.7) | 145 (50.5) | 6 (11.3) | 97 (55.4) | 80 (96.4) |
| 18 to 45 | 853 (57.7) | 247 (57.6) | 356 (78.8) | 133 (46.3) | 37 (69.8) | 77 (44.0) | 3 (3.6) |
| Older than 45 | 121 (8.2) | 40 (9.3) | 61 (13.5) | 9 (3.1) | 10 (18.9) | 1 (0.6) | 0 (0) |
| Sex, no. (% male) | 861 (58.2) | 223 (52.0) | 261 (57.7) | 192 (66.9) | 33 (62.3) | 103 (58.9) | 49 (59.0) |
| Type of donor, no. (%) | |||||||
| Related donor | 1193 (80.7) | 373 (86.9) | 327 (72.3) | 241 (84.0) | 48 (90.6) | 159 (90.9) | 45 (54.2) |
| Unrelated donor | 286 (19.3) | 56 (13.1) | 125 (27.7) | 46 (16.0) | 5 (9.4) | 16 (9.1) | 38 (45.8) |
| Source of stem cell, no. (%) | |||||||
| BM | 1416 (95.7) | 412 (96.1) | 443 (98.0) | 277 (96.5) | 39 (73.6) | 171 (97.7) | 74 (89.2) |
| PBSCs | 35 (2.4) | 11 (2.6) | 8 (1.8) | 2 (0.7) | 14 (26.4) | 0 (0) | 0 (0) |
| Cord blood | 28 (1.9) | 6 (1.4) | 1 (0.2) | 8 (2.8) | 0 (0) | 4 (2.3) | 9 (10.8) |
| Year of transplantation, no. (%) | |||||||
| 1974 to 1979 | 55 (3.7) | 18 (4.2) | 0 (0) | 12 (4.2) | 4 (7.5) | 21 (12.0) | 0 (0) |
| 1980 to 1984 | 224 (15.1) | 73 (17.1) | 41 (9.1) | 62 (21.6) | 6 (11.3) | 40 (22.9) | 2 (2.4) |
| 1985 to 1989 | 293 (19.8) | 88 (20.5) | 92 (20.4) | 52 (18.1) | 5 (9.4) | 34 (19.4) | 22 (26.5) |
| 1990 to 1994 | 450 (30.4) | 120 (28.0) | 180 (39.8) | 80 (27.9) | 7 (13.2) | 38 (21.7) | 25 (.0.1) |
| 1995 to 1998 | 457 (30.9) | 130 (30.3) | 139 (30.8) | 81 (28.2) | 31 (58.5) | 42 (24.0) | 34 (41.0) |
| Median time since HCT, mo (range) | 9.5 (2.0-28.4) | 10 (2.0-26.5) | 9.4 (2.1-21.9) | 9.2 (2.0-26.3) | 6.3 (2.1-27.7) | 13.1 (2.0-28.4) | 8.0 (2.1-19.0) |
| Conditioning regimen, no. (%) | |||||||
| TLI | 1279 (86.5) | 368 (85.8) | 423 (93.6) | 280 (97.9) | 48 (90.6) | 119 (68.0) | 41 (49.4) |
| Cyclophosphamide | 1066 (72.1) | 316 (73.7) | 318 (70.4) | 188 (65.7) | 43 (81.1) | 157 (89.7) | 44 (53.0) |
| Busulfan | 164 (11.1) | 77 (17.9) | 31 (6.9) | 10 (3.5) | 4 (7.5) | 0 (0) | 42 (50.6) |
| VP16 | 403 (27.3) | 129 (30.1) | 138 (30.5) | 124 (43.4) | 12 (22.6) | 0 (0) | 0 (0) |
| Cytarabine | 72 (4.9) | 35 (8.2) | 2 (0.4) | 35 (12.2) | 0 (0) | 0 (0) | 0 (0) |
| Disease status at HCT, no. (%) | |||||||
| High risk of relapse | 364 (24.7) | 142 (33.3) | 133 (29.5) | 68 (23.7) | 21 (41.2) | 0 (0) | 0 (0) |
| Chronic GVHD | 730 (49.7) | 206 (48.6) | 286 (63.3) | 119 (41.9) | 35 (67.3) | 66 (37.7) | 18 (21.7) |
| Institutions (%) | |||||||
| COH | 722 (48.8) | 230 (53.6) | 241 (53.3) | 159 (55.4) | 34 (64.2) | 58 (33.1) | 0 (0) |
| UMN | 757 (51.2) | 199 (46.4) | 211 (46.7) | 128 (44.6) | 19 (35.8) | 117 (66.9) | 83 (100) |
| No. of deaths (%) | 320 (21.6) | 107 (24.9) | 98 (21.7) | 71 (24.7) | 13 (24.5) | 19 (10.9) | 12 (14.5) |
| Median age at death, y (range) | 33.4 (2.7-63.7) | 33.4 (5.2-62.6) | 42.7 (5.0-63.7) | 25.1 (5.0-53.8) | 44.2 (19.7-62.2) | 29.8 (7.8-55.5) | 7.6 (2.7-17.5) |
| Relapse in the first 2 y of HCT (ie, before entry into cohort), no. (%) | |||||||
| History of relapse | 127 (8.6) | 36 (8.4) | 46 (10.2) | 35 (12.2) | 8 (15.1) | 2 (1.1) | 0 (0) |
| No history of relapse | 1352 (91.4) | 393 (91.6) | 406 (89.8) | 252 (87.8) | 45 (84.9) | 173 (98.9) | 83 (100) |
| Variables . | Entire cohort, n = 1479 . | Primary diagnosis . | |||||
|---|---|---|---|---|---|---|---|
| AML, n = 429 . | CML, n = 452 . | ALL, n = 287 . | NHL, n = 53 . | SAA, n = 175 . | IEM, n = 83 . | ||
| Median age at HCT, y (range) | 25.9 (0.2-71.5) | 26.2 (0.9-61.0) | 34.3 (1.1-71.5) | 17.8 (0.5-51.9) | 37.3 (5.7-53.3) | 16.9 (1.7-46.7) | 2.6 (0.2-32.9) |
| Age at transplantation, y (%) | |||||||
| Younger than 18 | 505 (34.1) | 142 (33.1) | 35 (7.7) | 145 (50.5) | 6 (11.3) | 97 (55.4) | 80 (96.4) |
| 18 to 45 | 853 (57.7) | 247 (57.6) | 356 (78.8) | 133 (46.3) | 37 (69.8) | 77 (44.0) | 3 (3.6) |
| Older than 45 | 121 (8.2) | 40 (9.3) | 61 (13.5) | 9 (3.1) | 10 (18.9) | 1 (0.6) | 0 (0) |
| Sex, no. (% male) | 861 (58.2) | 223 (52.0) | 261 (57.7) | 192 (66.9) | 33 (62.3) | 103 (58.9) | 49 (59.0) |
| Type of donor, no. (%) | |||||||
| Related donor | 1193 (80.7) | 373 (86.9) | 327 (72.3) | 241 (84.0) | 48 (90.6) | 159 (90.9) | 45 (54.2) |
| Unrelated donor | 286 (19.3) | 56 (13.1) | 125 (27.7) | 46 (16.0) | 5 (9.4) | 16 (9.1) | 38 (45.8) |
| Source of stem cell, no. (%) | |||||||
| BM | 1416 (95.7) | 412 (96.1) | 443 (98.0) | 277 (96.5) | 39 (73.6) | 171 (97.7) | 74 (89.2) |
| PBSCs | 35 (2.4) | 11 (2.6) | 8 (1.8) | 2 (0.7) | 14 (26.4) | 0 (0) | 0 (0) |
| Cord blood | 28 (1.9) | 6 (1.4) | 1 (0.2) | 8 (2.8) | 0 (0) | 4 (2.3) | 9 (10.8) |
| Year of transplantation, no. (%) | |||||||
| 1974 to 1979 | 55 (3.7) | 18 (4.2) | 0 (0) | 12 (4.2) | 4 (7.5) | 21 (12.0) | 0 (0) |
| 1980 to 1984 | 224 (15.1) | 73 (17.1) | 41 (9.1) | 62 (21.6) | 6 (11.3) | 40 (22.9) | 2 (2.4) |
| 1985 to 1989 | 293 (19.8) | 88 (20.5) | 92 (20.4) | 52 (18.1) | 5 (9.4) | 34 (19.4) | 22 (26.5) |
| 1990 to 1994 | 450 (30.4) | 120 (28.0) | 180 (39.8) | 80 (27.9) | 7 (13.2) | 38 (21.7) | 25 (.0.1) |
| 1995 to 1998 | 457 (30.9) | 130 (30.3) | 139 (30.8) | 81 (28.2) | 31 (58.5) | 42 (24.0) | 34 (41.0) |
| Median time since HCT, mo (range) | 9.5 (2.0-28.4) | 10 (2.0-26.5) | 9.4 (2.1-21.9) | 9.2 (2.0-26.3) | 6.3 (2.1-27.7) | 13.1 (2.0-28.4) | 8.0 (2.1-19.0) |
| Conditioning regimen, no. (%) | |||||||
| TLI | 1279 (86.5) | 368 (85.8) | 423 (93.6) | 280 (97.9) | 48 (90.6) | 119 (68.0) | 41 (49.4) |
| Cyclophosphamide | 1066 (72.1) | 316 (73.7) | 318 (70.4) | 188 (65.7) | 43 (81.1) | 157 (89.7) | 44 (53.0) |
| Busulfan | 164 (11.1) | 77 (17.9) | 31 (6.9) | 10 (3.5) | 4 (7.5) | 0 (0) | 42 (50.6) |
| VP16 | 403 (27.3) | 129 (30.1) | 138 (30.5) | 124 (43.4) | 12 (22.6) | 0 (0) | 0 (0) |
| Cytarabine | 72 (4.9) | 35 (8.2) | 2 (0.4) | 35 (12.2) | 0 (0) | 0 (0) | 0 (0) |
| Disease status at HCT, no. (%) | |||||||
| High risk of relapse | 364 (24.7) | 142 (33.3) | 133 (29.5) | 68 (23.7) | 21 (41.2) | 0 (0) | 0 (0) |
| Chronic GVHD | 730 (49.7) | 206 (48.6) | 286 (63.3) | 119 (41.9) | 35 (67.3) | 66 (37.7) | 18 (21.7) |
| Institutions (%) | |||||||
| COH | 722 (48.8) | 230 (53.6) | 241 (53.3) | 159 (55.4) | 34 (64.2) | 58 (33.1) | 0 (0) |
| UMN | 757 (51.2) | 199 (46.4) | 211 (46.7) | 128 (44.6) | 19 (35.8) | 117 (66.9) | 83 (100) |
| No. of deaths (%) | 320 (21.6) | 107 (24.9) | 98 (21.7) | 71 (24.7) | 13 (24.5) | 19 (10.9) | 12 (14.5) |
| Median age at death, y (range) | 33.4 (2.7-63.7) | 33.4 (5.2-62.6) | 42.7 (5.0-63.7) | 25.1 (5.0-53.8) | 44.2 (19.7-62.2) | 29.8 (7.8-55.5) | 7.6 (2.7-17.5) |
| Relapse in the first 2 y of HCT (ie, before entry into cohort), no. (%) | |||||||
| History of relapse | 127 (8.6) | 36 (8.4) | 46 (10.2) | 35 (12.2) | 8 (15.1) | 2 (1.1) | 0 (0) |
| No history of relapse | 1352 (91.4) | 393 (91.6) | 406 (89.8) | 252 (87.8) | 45 (84.9) | 173 (98.9) | 83 (100) |
AML indicates acute myeloid leukemia; CML, chronic myeloid leukemia; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; SAA, severe aplastic anemia; IEM, inborn errors of metabolism; BM, bone marrow; PBSC, peripheral blood stem cells; and TLI, total body irradiation.